FDA Taking “Risk-Based Approach” To Sequestration Cuts
This article was originally published in The Rose Sheet
The agency will try to manage $319 million in potential funding reductions in a way that minimizes negative effects on health and safety, FDA Commissioner Hamburg tells the Science Board, but significant layoffs seem unavoidable if sequestration is enacted.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions written record; negotiations for BsUFA III may be opportunity to create such a process.
CDER director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.